Abstract: The objective of this paper was to investigate the therapeutic effects of EA-PAOA on the immune hepatic injury in Kunming mice and study its therapeutic mechanisms. Kunming mice were divided into five groups, which were normal control, model control, test 1(EA-PAOA 0.5 g/kg), test 2(EA-PAOA 1 g/kg), test 3 (EA-PAOA 2 g/kg). Model control and three test groups, respectively, received intravenous injections of Concanavalin A(20 mg/kg) 0.5 mL, once one day, five days in all. Two hours after the first injection of Concanavalin A, three test groups were administrated intraperitoneal injections of EA-PAOA 0.5 mL, three times one day, five days in all.Six hours after the last injection of EA-PAOA, blood were collected, the liver was reserved for routine light microscopy and the spleen was aimed to do T-cell proliferaction activity tests. We tested the effects of EA-PAOA on T lymphocyte subsets of spleen with flow cytometry. Compared to model control group, in the three EA-PAOA tests, the level of serum ALT,IFN-γ,TNF-α were lower,serum IL-10 were higher(P<0.01) .EA-PAOA could obviously inhibit T-cell proliferactive activity. But the number of CD4+ T and CD8+ T lymphocyte in spleen with flow cytometry hadn’t much difference. The results indicated that EA-PAOA had distinct anti-liver injury function. Therefore, we suppose that the therapeutic mechanisms of EA-PAOA could be to inhibit T-cell proliferaction activity, increase serum concentration of IL-10, and decrease serum concentration of IFN-γ,TNF-α. 

Key words: liver injury; concanavalin A; EA-PAoA; T-cell proliferaction activity